Kornimate/medical-research-clean huggingface dataset:
anshen buxin liuwei pills for the treatment of cardiac neurosis

Conditions: Cardiac Neurosis

Summary: this study aims to assess the effect and safety of the traditional mongolian medicine anshen buxin liuwei pill for the treatment of cardiac neurosis.

cardiac neurosis is a group of symptoms characterized by the coexistence of cardiovascular disease related symptoms and nervous system disorders. anshen buxin liuwei pill is a kind of traditional mongolian medicine for the treatment of cardiac neurosis. this study aims to evaluate the effect and safety of anshen buxin liuwei pill for cardiac neurosis in a prospective, randomized, double-blind, placebo-controlled clinical trial.

Eligibility criteria:
inclusion criteria: * age ≥18 years old, ≤75 years old; * meet the diagnostic criteria for cardiac neurosis: the patient has palpitations, precordial pain, chest tightness, shortness of breath, dyspnea, dizziness, insomnia and dreaminess, cold hands and feet, hyperhidrosis and other cardiovascular symptoms and neurological disorders; * meet the diagnostic criteria of heyisheng type palpitations in mongolian medicine; * there is no objective diagnosis of coronary heart disease (in accordance with any of the following): ①the activity flat test is negative; ② coronary angiography or coronary cta suggests that the lumen stenosis is ≤50%; ③ exercise or drug load radionuclide examination results suggest no myocardial ischemia; * the patient did not take anti-anxiety and depression drugs or psychotropic drugs within 2 weeks before enrollment; * agrees to voluntarily participate in the study and signs an informed consent form . exclusion criteria: * accompanied by organic heart disease, severe cardiopulmonary insufficiency; * poor hypertension control (systolic blood pressure ≥160mmhg or diastolic blood pressure ≥100mmhg after treatment); * those with malignant arrhythmia; * those who use pacemakers; * patients with hyperthyroidism; * combined with severe liver and kidney damage (alt, ast or tbil\> 2 times the upper limit of the normal reference value, or cr\> 1.5 times the upper limit of the normal reference value); * people with serious primary diseases such as hematopoietic system or mental illness; * sas≥70; * sds≥73; * accompanying any other serious diseases or conditions such as malignant tumors; * women during pregnancy and lactation; * people with allergies or allergies to the known ingredients of the research drug; * participated in other clinical research in the past 3 months; * according to the judgment of the investigator, the subject is not suitable for research observation.
evaluating the effects of tradipitant vs. placebo in atopic dermatitis (epione2)

Conditions: Atopic Dermatitis

Summary: this is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the united states in subjects with atopic dermatitis.


Eligibility criteria:
inclusion criteria: * male and non-pregnant, non-lactating female patients aged 18 - 70 years (inclusive); * diagnosed with atopic dermatitis; * suffering from chronic pruritus; * body mass index (bmi) of ≥18 and ≤40 kg/m2 exclusion criteria: * chronic pruritus due to condition other than atopic dermatitis (ad); * a positive test for drugs of abuse at the screening or evaluation visits; * exposure to any investigational medication in the past 60 days

Keywords: chronic pruritus eczema
kidney coordinated health management partnership

Conditions: Chronic Kidney Diseases

Summary: as part of a 42-month pragmatic, cluster randomized trial in 1,650 primary care patients with high-risk chronic kidney disease (ckd), the investigators will test the effectiveness of a multifaceted electronic health record (ehr)-based population health management (phm) intervention that targets improvements in the delivery of evidence-based ckd care.

to test the effectiveness of a multifaceted electronic health record (ehr)-based population health management (phm) intervention to improve the delivery of evidence-based chronic kidney disease (ckd) care in patients with high-risk ckd. investigators will perform a 42-month pragmatic, cluster randomized (at the practice level) controlled trial in 1,650 patients with high-risk ckd (as defined by validated risk prediction models or by current estimated glomerular filtration rate (egfr) value or recent decline in egfr values) managed by their primary care physicians (pcps) to determine whether ehr-based phm improves key processes of care and clinical outcomes. the investigators hypothesize that ehr-based phm will improve hypertension control, use of renin angiotensin aldosterone system inhibitors (raasi), and avoidance of renally contraindicated medications (aim 1a-1c) and delay ckd progression (aim 2). investigators will also characterize the acceptability and experience of primary care physicians (pcps) in the intervention arm of the ckd phm study (aim 3).

Eligibility criteria:
inclusion criteria for pcps: presence of an ambulatory continuity clinic in the university of pittsburgh medical center (upmc) community medicine practice. inclusion criteria for patients: 1. age greater than or equal to 18, and less than or equal to 85 2. most recent egfr less than 60 ml/min/yr 3. established care with upmc pcp 4. high risk ckd based on validated external and internal risk prediction models or severe reduction in egfr, or substantial loss in egfr in prior 18 months. exclusion criteria for pcps: none exclusion criteria for patients: 1. history of kidney transplant 2. receiving maintenance dialysis 3. recent (within 12 months) outpatient nephrology visit 4. baseline egfr less than 15ml/min 5. expected survival less than 6 months or hospice enrollee (e.g., stage iv heart failure, metastatic cancer, oxygen dependent chronic obstructive pulmonary disease)

Keywords: electronic health record population health management patient education medication therapy management electronic consultation randomized controlled trial pragmatic trial
interstitial lung disease trajectories in patients with systemic sclerosis

Conditions: Systemic Sclerosis; Interstitial Lung Disease

Summary: systemic sclerosis (ssc) is a heterogeneous systemic autoimmune disease with distinct prognosis according to patients. in patients with systemic sclerosis, interstitial lung disease (ild) concerns almost 50 % of patients and represents the main cause of mortality. disease course in ssc-ild is highly variable: patients can experience stable disease, slow or fast progression. prevention of ild progression now represents a key objective of ssc-ild management. the understanding of the course and patterns of ssc-ild progression is necessary, as reliable prediction tools that allow the stratification of the risk of progression. we aimed to identify the longitudinal trajectories of ild in ssc patients using latent class mixed models and to examine their associations with ssc characteristics.


Eligibility criteria:
inclusion criteria: * patients with systemic sclerosis according to 2013 acr/eular criteria * patients with interstitial lung disease on hrct chest * patients with pft at ild diagnosis and at least 1 pft evaluation during follow-up exclusion criteria: * patients with an alternative diagnosis of ssc-associated ild (silicosis, sarcoidosis, lung cancer or other significant lung abnormalities)
use of 3,4-diaminopyridine in the treatment of lambert-eaton syndrome

Conditions: Lambert Eaton Myasthenic Syndrome

Summary: to learn more about the effect of 3, 4-diaminopyridine (3,4-dap) on patient diagnosed with lambert-eaton myasthenic syndrome (lems).


Eligibility criteria:
inclusion criteria: * age 18 years or older, * diagnosed with lems, * if female, have a negative pregnancy test, and * if premenopausal, be willing to practice an effective form of birth control during the study, * tested and found by ecg not to have a prolonged qt syndrome, * agree to have a second ecg at the time of peak drug effect, * has understood and signed the informed consent. exclusion criteria: * is known to have a sensitivity to 3, 4-dap, * has a history of: 1. past or current seizures, 2. cardiac arrhythmia, 3. hepatic, renal or hematologic disease, or 4. severe asthma, * is believed by the investigator to be unable to comply with the protocol.
effects of core stabilization exercise plus kinesio taping in woman with fibromyalgia

Conditions: Fibromyalgia; Exercise; Rheumatic Diseases

Summary: this study aimed to compare the effectiveness of a 6-week core stabilization exercise (cse) program with and without kinesio taping on pain, fatigue, health status, quality of life, sleep quality and depression in woman with fibromyalgia. participants were allocated into two groups as cse and cse plus kinesio taping group. pain, fatigue, health status, quality of life, sleep quality and depression were assessed at the baseline and after 6-weeks treatment.

a 6-weeks prospective randomized controlled trial examined the effects of core stabilization exercise (cse) plus kinesio taping (kt) compared to cse alone on pain, fatigue, health status, quality of life, sleep quality and depression in woman with fm. the trial was approved by the ethics committee of ankara yildirim beyazit university (approval time and number: 17.01.2018-14). the study was performed in compliance with helsinki declaration where applicable. the patient's recruitment started in february 2018. the patients diagnosed with fibromyalgia according to the criteria of the 1990 american college of rheumatology participated in the study. prior to the treatment and after 6-weeks treatment, participants' pain level, fatigue, health status, quality of life (qol), psychological status and sleep quality were assessed. assessments were realized by face-to-face interview method.patients who participated in cse group performed cse program alone, whereas patients in cse+kt group performed cse program with kt application. the treatment was carried out 2 days a week for 6 weeks.

Eligibility criteria:
inclusion criteria: * diagnosed with fibromyalgia, being woman, having moderate or severe pain according to visual analog scale, 18-65 years of age and being volunteer for the study exclusion criteria: * having neurologic, infectious, and endocrine diseases, malignancy, being pregnant, severe psychological disorders, any changing of medications during treatment, being allergic to taping, any condition interfering with exercise (advanced cardiac, respiratory or musculoskeletal problems), and intervention including exercise program or physical therapy in the last 6 months.

Keywords: fibromyalgia exercise kinesio taping
lumbar plexus block upon the incidence of ischemic cardiovascular events in elderly patients with hip fracture

Conditions: Hip Fractures; Perioperative Myocardial Ischemia

Summary: the purpose of this study is evaluate the efficacy of perioperative continuous lumbar plexus block in reducing the risk of cardiac ischemic events of elderly patients undergoing surgery for hip fractures, expressed as a reduction of ischemic events per subject.


Eligibility criteria:
inclusion criteria: * patients with hip fracture within 48 hours of evolution * known coronary artery disease: previous myocardial infarction chronic stable angina atypical angina with positive exercise test for coronary flow failure. evidence of coronary artery disease with ultrasound, scintigraphic or angiographic compatible * patients with at least two of the risk factors for coronary heart disease as defined by wallace (1998) exclusion criteria: * patients receiving orthopedic treatment. * patients with coagulopathy, clinic or laboratory. * patients with sepsis or infection of the catheter insertion site of lumbar plexus. * patients with neurological diseases evolving. * patients disoriented, or dementia. * ckd stage iv national kidney foundation (2) * glomerular filtration rate between 15 and 29 ml/min/1, 73 m2 * patients unable to use the numeric rating scale (nrs) to assess pain. * patients with non-sinus rhythm or conduction abnormalities (right bundle branch block or left, atrioventricular block) in the admission ecg * patients with pacemaker. * enrolled patients with acute coronary syndrome or decompensated cardiovascular disease at entry. * allergy to any of the drugs of the protocol. * inability to understand or unaided sign informed consent.

Keywords: continuous lumbar plexus (lp) block analgesia
a study to show that the change of attention measure is correlated with the changes of caregiver's burden after treatment with galantamine in patients with alzheimer's disease

Conditions: Alzheimer's Disease

Summary: the purpose of this study is to demonstrate that the change of attention measure is correlated with the changes of caregiver's burden after treatment with galantamine.

this is an open-label (all people know the identity of the intervention), prospective (in which the participants are first identified and then followed forward as time passes), observational (study in which the investigators/ physicians observe the patients and measure their outcomes), multi-center (study conducted at multiple sites) study. the study mainly consists of 2 phases including, the screening phase (14 days before administration of study medication) and treatment phase (16 weeks). in the treatment phase, patients will receive galantamine 8 mg/day for the first 4 weeks and later on the dose will be increased up to 24mg (if tolerable). safety evaluations will include assessment of adverse events. the total duration of the study will be 18 weeks.

Eligibility criteria:
inclusion criteria: * alzheimer's disease according to the criteria of diagnostic and statistical manual of mental disorders, fourth edition (dsm-iv), national institute of neurological and communicative diseases and stroke-alzheimer's disease and related disorders association (nincds-adrda) * measuring standard: k-mmse is 10 to 24 * patient with reliable guardian exclusion criteria: * patients with brain tumor, nerve syphilis, meningitis, encephalitis, epilepsy * major psychiatric patients such as major depression and schizophrenia * patients with treatment-resistant gastric and peptic ulcer * patients with clinically serious hepatic, renal, lung, endocrinal or metabolic disease (thyroid, parathyroid, pituitary, renal failure, diabetes mellitus)

Keywords: alzheimer's disease caregiver's burden in alzheimer's disease galantamine razadyne reminyl
immunological repertoire in patients with lymphoma and chronic lymphocytic leukemia

Conditions: LYMPHOMA

Summary: ripal is a prospective cohort study, which main goal is to define t and b immune repertoire diversity and magnitude in patients with non-hodgkin lymphoma of high and low grade and chronic lymphocytic leukemia before and after treatment, and to evaluate the association of these parameters with clinical patient data and outcomes.

constitution of a prospective cohort of 128 patients with 8 different groups of patients. this protocol is designed to evaluate a new tool for detecting the diversity of the repertoire t and b in patients with hematological disease. this in vitro diagnostic device is consisting of molecular biology kits human immuntracker® and human immun'igh® and the analysis tool ndl®

Eligibility criteria:
inclusion criteria: * 18 years and older * subjects with a diagnosis of large b-cell lymphoma, follicular lymphoma, mantle cell lymphoma, malt, marginal zone, waldenstrom's disease, chronic lymphocytic leukemia, t-cell lymphoma, anaplastic, cytotoxic or peripheral unspecified angioimmunoblastic. * have signed an informed consent for participation in the study and preservation of blood samples for biomedical research. * accept to appear in consultation biological samples at the sampling points corresponding to its group. * the benefits of social security. exclusion criteria: * subjects with a diagnosis of hodgkin disease * subjects with a diagnosis of t-prolymphocytic leukemia * subjects with a diagnosis of burkitt's lymphoma * subjects with a diagnosis of lymphoblastic lymphoma * subjects who had prior-treatment for hematological disease * patients under judicial safeguards

Keywords: chronic lymphocytic leukemia non-hodgkin lymphoma follicular lymphoma diffuse large b cell lymphoma malt lymphoma t cell lymphoma immune repertoire infection relapse survival treatment response vj rearrangement
prediction of patient-specific outcomes after interventional neuroradiology procedures

Conditions: Aneurysmal Disease; Stroke

Summary: stroke is either an obstruction (ischemic stroke) or the rupture of a blood vessel in the brain (ruptured aneurysm). it can happen at any age in adults. because of the risk of irreversible brain damage, it is an absolute medical emergency. an ischemic stroke (stroke) is the result of a lack of oxygen supply to a part of the brain. it can be one of many causes of stroke as a result of a thrombosis (occlusion) of the internal carotid artery or a cerebral embolism (migration of a clot or debris of fatty deposits) from a carotid stenosis. in both cases part of the brain is less irrigated. there will then be a neurological deficit (paralysis) more or less important corresponding to the affected cerebral territory. the deficit may concern the whole hemicorps (hemiplegia) or a part of the body (upper or lower limb) and sometimes is associated with facial paralysis and/or language disorders. a brain aneurysm occurs when the wall of an intracranial artery expands abnormally, creating a pocket of blood. it is often caused by weakness in the vascular tissue, but it can also occur later in life due to illness, head injury, oral contraceptives or certain lifestyle habits (smoking, excessive alcohol consumption). sudden increases in pressure due to stress or strenuous exercise can serve as a trigger. interventional neuroradiology (inr) is a medical specialty that manages stroke patients using imaging to perform the medical procedure and thereby limit openings and their associated risks. this specialty has a growing place in modern medicine. in order to improve the quality of care, patient safety and functional outcomes, it is necessary to keep patient information. a database storing patient data from the nri department will make it possible to track patients since their arrival at the brest university hospital. thanks to this structured database, clinical studies will be facilitated, making it possible to advance knowledge of the pathology and its treatments. from the bibliographical research, we can conclude as to the current state of the facts: there is currently no method for predicting the functional results of the interventional neuroradiologist's patient based on automated learning. a strategy based on an innovation programme is therefore being implemented over several years, the first stage of which is the retrospective data study which was approved by the ethics committee on 12/09/2019 and the second stage is the prospective data study. this innovation program requires the most complete and homogeneous data possible.


Eligibility criteria:
inclusion criteria: - major patient carrying either a small or large, ruptured or unruptured aneurysm or a thrombectomy, with in both cases, a treatment procedure carried out in the interventional neuroradiology department of the brest chru. exclusion criteria: * age \< 18 years old * incapacitated patients of full age (under guardianship or curatorship) * refusal to participate * follow-up impossible

Keywords: thrombectomy aneurysm
severe heart failure and homebased rehabilitation - an intersectoral randomized controlled trial

Conditions: Chronic Heart Failure; Heart Failure NYHA Class II; Heart Failure NYHA Class III; Heart Failure NYHA Class IV

Summary: the purpose of this study is to investigate the effect of an early, coordinated rehabilitation intervention for patients with severe heart failure in nyha class iii and iv with a ejection fraction of \<40% of normal cardiac function measured on frequency of readmissions, physical ability and participation in activities of daily living and quality of life.

approximately 400,000 danes live today with heart disease. disease severity is crucial for patients quality of life. patients with severe heart disease often struggle with everyday life, characterized by reduced physical capacity, tendency to depression and anxiety to perform everyday activities that may provoke symptoms. a large proportion of patients who are offered cardiac rehabilitation deselect that offer. of the patients who do participate, more than 50% stop the rehabilitation ahead of time. a large group of patients with severe heart failure and classified in nyha class iii and iv, deselect the offer because of lack of energy to participate in cardiac rehabilitation or is when specified by a medical assessment discharged from the hospital without the offer of training or any other form of rehabilitation. the offer of rehabilitation for patients with severe heart failure is lacking as it is today. this study assesses the effectiveness of an early home based rehabilitation program that complements the general psycho-social support, symptom-oriented and preventive medical treatment that these patients always have the option to get.

Eligibility criteria:
inclusion criteria: * patients admitted to the gentofte hospital due to heart failure. * patients with a functional equivalent to nyha grade iii or iv * patients with ejection fraction \<40% * patients who score between10-15 in the total score for question 3 dealing with physical functioning in sf-36 questionnaire on health status * patients who lives in gentofte municipality or lyngby tårbæk municipality. * patients who can speak and understand danish exclusion criteria: * patients with cognitive and psychological problems that prevents cooperation (aphasia, dementia, severe depression). * patients with terminal illness with expected death within a year.

Keywords: severe heart failure homebased rehabilitation physical exercise activities of daily living intersectoral cooperation